Angel in Need is dedicated to supporting cancer patients and their families by raising essential funds. Through various initiatives and community efforts, the organization aims to alleviate some of the financial burdens that come with a cancer diagnosis, ensuring that those affected receive the assistance they need during such challenging times. By fostering a spirit of compassion and solidarity, Angel in Need plays a crucial role in providing hope and support to individuals and families navigating the hardships of cancer treatment.
Scan the code to donate
Angel in Need is dedicated to supporting cancer patients and their families by raising essential funds. Through various initiatives and community efforts, the organization aims to alleviate some of the financial burdens that come with a cancer diagnosis, ensuring that those affected receive the assistance they need during such challenging times. By fostering a spirit of compassion and solidarity, Angel in Need plays a crucial role in providing hope and support to individuals and families navigating the hardships of cancer treatment.
We highlight some of the many innovations showcased at the inaugural AACR Drug Discovery and Development (AACR D3) conference, including investigational KRAS degraders, approaches to drug p53 and MYC, and new AI tools for drug discovery.
The post AACR D3 Offered a Peek Into the Cancer Drug Pipeline, Innovative AI Tools, and More appeared first on American Association for Cancer Research (AACR).
The AACR D3 edition of “From the Bench” highlights cutting-edge approaches from the meeting that could shape the next generation of cancer treatments. We spoke with Andrea Wang-Gillam, MD, PhD, of Jacobio Pharmaceuticals; Kiyean Nam, PhD, of Qurient; Sharanya Nag, PhD, of Memorial Sloan Kettering Cancer Center; and Giuseppina Carbone, MD, about their innovative strategies to inhibit KRAS, enhance antibody-drug conjugate efficacy, and tackle resistance.
The post From the Bench, AACR D3 2026: Emerging Therapeutic Strategies to Inhibit KRAS, Enhance ADCs, and Tackle Resistance appeared first on American Association for Cancer Research (AACR).
With seven CAR T-cell therapies approved by the U.S. Food and Drug Administration, this innovative immunotherapy has revolutionized the treatment of blood cancers in recent years. Here, we provide an overview of how this therapy works and which cancers it’s approved to treat.
The post What Is CAR T-cell Therapy? appeared first on American Association for Cancer Research (AACR).
In July, the editors from AACR’s 10 peer-reviewed journals highlighted research on AI-driven molecular mapping of pancreatic cancer evolution, sex differences in immune responses, the discovery of a new subset of cells that promote brain metastasis, along with several other exciting articles.
The post Editors’ Picks, July 2026: AI-powered Pancreatic Proteomics, Sex-based Immune Differences, and More appeared first on American Association for Cancer Research (AACR).
The summer issue of Cancer Today includes articles about integrating patient-reported outcomes into clinical research and care, advances in preventing and treating graft-versus-host disease, researchers’ efforts to better understand the mechanisms of treatment resistance, advice about divulging a cancer diagnosis when dating, and more.
The post Cancer Today’s Summer 2026 Issue: Using Patient-reported Outcomes to Address Side Effects, Preventing Graft-versus-host Disease, and More appeared first on American Association for Cancer Research (AACR).
During the opening session of the AACR Conference on Drug Discovery and Development, the conference cochairs—Patricia M. LoRusso, DO, PhD (hc), FAACR; Keith T. Flaherty MD, FAACR; Lillian L. Siu, MD, FAACR; and Timothy A. Yap, MBBS, PhD—led a panel discussion with leading voices from industry and venture capital, including Alexis Borisy, MS, cofounder and chairman of the venture capital firm Curie.Bio; Chris Boshoff, MD, PhD, chief scientific officer and president of research and development at Pfizer; and David Schenkein, MD, general partner of the venture capital firm Google Ventures.
The post Inaugural AACR D3 Opens With Insights From Leaders Across Drug Discovery and Development appeared first on American Association for Cancer Research (AACR).
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.